Multiple early factors anticipate post-acute COVID-19 sequelae
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific auto-antibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes, exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time, leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
Cell - 185(2022), 5 vom: 03. März, Seite 881-895.e20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Yapeng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2022 Date Revised 17.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cell.2022.01.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337481814 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337481814 | ||
| 003 | DE-627 | ||
| 005 | 20231225234515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cell.2022.01.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337481814 | ||
| 035 | |a (NLM)35216672 | ||
| 035 | |a (PII)S0092-8674(22)00072-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Yapeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiple early factors anticipate post-acute COVID-19 sequelae |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2022 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific auto-antibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes, exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time, leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a PASC | |
| 650 | 4 | |a RNAemia | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a auto-antibodies | |
| 650 | 4 | |a computational biology | |
| 650 | 4 | |a immune system | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a long COVID | |
| 650 | 4 | |a metabolomics | |
| 650 | 4 | |a multi-omics | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a single cell | |
| 650 | 4 | |a single-cell CITE-seq | |
| 650 | 4 | |a single-cell RNA-seq | |
| 650 | 4 | |a single-cell TCR-seq | |
| 650 | 4 | |a single-cell secretome | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a transcriptome | |
| 650 | 4 | |a viremia | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Proteins |2 NLM | |
| 700 | 1 | |a Yuan, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Daniel G |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Rachel H |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jongchan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Sunga |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Rongyu |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Jingyi |e verfasserin |4 aut | |
| 700 | 1 | |a Kornilov, Sergey A |e verfasserin |4 aut | |
| 700 | 1 | |a Scherler, Kelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlovitch-Bedzyk, Ana Jimena |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Lausted, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Inyoul |e verfasserin |4 aut | |
| 700 | 1 | |a Fallen, Shannon |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Chengzhen L |e verfasserin |4 aut | |
| 700 | 1 | |a Baloni, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Duvvuri, Venkata R |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Kristin G |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Duncombe, Caroline J |e verfasserin |4 aut | |
| 700 | 1 | |a McCulloch, Denise J |e verfasserin |4 aut | |
| 700 | 1 | |a Rostomily, Clifford |e verfasserin |4 aut | |
| 700 | 1 | |a Troisch, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Mackay, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a DeGottardi, Quinn |e verfasserin |4 aut | |
| 700 | 1 | |a May, Damon H |e verfasserin |4 aut | |
| 700 | 1 | |a Taniguchi, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Gittelman, Rachel M |e verfasserin |4 aut | |
| 700 | 1 | |a Klinger, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Snyder, Thomas M |e verfasserin |4 aut | |
| 700 | 1 | |a Roper, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Wojciechowska, Gladys |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Edmark, Rick |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Lesley |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Rowen, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Chour, William |e verfasserin |4 aut | |
| 700 | 1 | |a Algren, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Berrington, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Wallick, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Cochran, Rebecca A |e verfasserin |4 aut | |
| 700 | 1 | |a Micikas, Mary E |e verfasserin |4 aut | |
| 700 | 0 | |a ISB-Swedish COVID-19 Biobanking Unit |e verfasserin |4 aut | |
| 700 | 1 | |a Wrin, Terri |e verfasserin |4 aut | |
| 700 | 1 | |a Petropoulos, Christos J |e verfasserin |4 aut | |
| 700 | 1 | |a Cole, Hunter R |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Trevan D |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Hoon, Dave S B |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Nathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanian, Naeha |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Hadlock, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Magis, Andrew T |e verfasserin |4 aut | |
| 700 | 1 | |a Ribas, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Lanier, Lewis L |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, Scott D |e verfasserin |4 aut | |
| 700 | 1 | |a Bluestone, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Hood, Leroy |e verfasserin |4 aut | |
| 700 | 1 | |a Gottardo, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Greenberg, Philip D |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Goldman, Jason D |e verfasserin |4 aut | |
| 700 | 1 | |a Heath, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell |d 1974 |g 185(2022), 5 vom: 03. März, Seite 881-895.e20 |w (DE-627)NLM000088935 |x 1097-4172 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2022 |g number:5 |g day:03 |g month:03 |g pages:881-895.e20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cell.2022.01.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 185 |j 2022 |e 5 |b 03 |c 03 |h 881-895.e20 | ||